FDG-PET imaging has significantly altered the workup of the oncologic patient. With the introduction of combined FDG-PET/CT scanners, there has been a dramatic improvement in lesion detection, lesion characterization and accurate lesion localization. As attenuation correction can be attained with the CT images, PET exam times have been dramatically reduced, by as much as 50% in many instances. In this overview we briefly outline the advantages of CT/PET in oncology especially in diagnosis and clinical management of the common tumor types for which it is mainly used.
Introduction
Fluorine-18 fluorodeoxyglucose ([ 18 F]FDG) is currently the most common agent used in PET imaging. Normal tissues utilize glucose for energy and FDG is a glucose analog that is taken up by cells and then trapped intracellularly in this pathway. Most tumors tend to favor this pathway and therefore tend to appear more active ('hotter') than normal tissues. However, both benign and malignant processes can be FDG avid. Furthermore, normal physiologic uptake can simulate or obscure disease (i.e. brain uptake, muscle uptake after exercise, cardiac activity in the non-fasting state and uptake in brown fat (Fig. 1) .
Several cancers can be diagnosed and staged using [ 18 F]FDG-PET with accuracies ranging from 80% to 98%. In addition, response to therapy assessment and prognostic information can be obtained from [ 18 F]FDG-PET images. Although there was an already high performance for [ 18 F]FDG-PET images, they lacked spatial resolution, even with attenuation correction schemes. Fusion of CT and PET images was developed with some success. But as these images were acquired separately and later fused, there were problems with accurate localization [1] . The development of a dedicated CT/PET system by Townsend et al. has overcome many of the problems that fusing CT and PET images has [1] . In addition acquisition times for PET/CT images are much shorter. PET/CT in general has improved reader confidence in lesion detection, localization, as well as characterization, leading to a marked reduction in indeterminate or equivocal findings. In addition, as the CT images are used for attenuation correction, acquisition times are much shorter, by up to 50% [2] .
The added advantages of combined PET/CT images are its ability to overcome the limitations of size criteria used to suggest the presence of tumor deposits in normal sized lymph nodes (Fig. 2) , and its ability to localize and characterize the functional aspect of an anatomic finding. Therefore combined CT/PET images offer the advantage of demonstrating metabolism and structure simultaneously [2] [3] [4] [5] . [6, 7] . CT/PET is also useful in radiotherapy treatment planning, and in one study gross tumor volume (GTV) delineation was increased by 25% or more in 17% of head and neck and lung cancers respectively and 33% of pelvic tumors. GTV was reduced by 25% or less in 33% of head and neck cancers, 67% of lung cancers and 19% of pelvic cancers. Overall treatment volume was altered in 56% of patients using CT/PET [6] .
Head and neck cancer
In a study of 68 patients with 157 sites of uptake, with [ 18 F]FDG-PET alone, 71 malignant, 45 benign and 39 equivocal lesions were demonstrated (Table 1) . With [ 18 F]FDG-PET/CT, there was a decrease in equivocal lesions of 53%, and accuracy improved from 90% to 96%. Six proven malignancies were missed with PET and only one with PET/CT. In addition accurate anatomic localization was achieved in 100 lesions and overall management was impacted in 18% [8] . (Table 2) . It demonstrated accurate localization of metastatic lymph nodes in nine, accurate determination of chest wall involvement in three, mediastinal invasion in three, and the presence of distant metastases in two instances (Fig. 6 ). It was also helpful in distinguishing tumor from atelectasis/inflammation in seven cases [9] . Adapted from Schoder et al. [8] . Adapted from Lardinois et al. [9] . (Tables 3 and 4) . Overall staging accuracy improved from 78% to 89% on a patient-by-patient analysis (Fig. 7 ) [10, 11] .
Lung cancer
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Colon cancer
Figure 3
A 67-year-old man diagnosed with esophageal cancer. Unenhanced CT scan showed a large GE junction tumor (arrow) and an enlarged lesser gastric curvature lymph node (arrow), as well as a large hypodense lesion in the left hepatic lobe (arrowhead). FDG-PET/CT showed intense metabolic activity in the primary tumor, confirmed regional metastatic lymphadenopathy in the lesser curvature lymph node and demonstrated lack of FDG avidity in the liver lesion, which was shown to be a large hepatic hemangioma by other imaging methods.
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In another study of 65 patients with suspected or known colorectal carcinoma, sensitivity and specificity for PET/CT was 96% and 97% compared to 77% and 89% for PET alone. Similarly the sensitivity and specificity for metastases detection were 95% and 98% for PET/CT compared to 66% and 79% for PET alone [12] [13] [14] . Adapted from Cohade et al. [11] . Adapted from Cohade et al. [11] . Adapted from Freudenberg et al. [16] . Adapted from Mikhaeel et al. [20] .
Lymphoma
Overall staging specificity for both Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) using PET is superior to CT (Fig. 8(a), (b) ). PET usually has a specificity that is about 15% higher than that of CT for primary staging of lymphoma [15] . In a study of 27 patients who presented for restaging of lymphoma, PET and CT were compared with PET/CT for staging accuracy. On a patient-based evaluation, CT had a sensitivity of 78%, PET 86%, and PET/CT 93% (Table 5) . Using a region-based analysis for lymph node involvement, CT had a sensitivity of 61%, PET 78%, and PET/CT 96%. FDG-PET/CT is accurate in restaging lymphoma and has advantages over CT and FDG-PET alone [16] .
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Melanoma
In a prospective study of 106 patients with Stage III disease, unsuspected metastases were detected in 15%. The overall sensitivity and specificity for lesion detection were 92% and 90% and FDG-PET changed overall management in 22% of patients (Fig. 9) [17] . In another study of 84 patients with recurrent melanoma, FDG-PET had a therapeutic impact in 26%: upstaging one-third and downstaging two-thirds of cases [18] . This study shows that PET has a major impact on the management of patients who are scheduled to undergo radiotherapy [19] . Keynote lecture S75
Impact of [
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FDG-PET and monitoring response to therapy
Conventional anatomical imaging with CT and MRI are limited in assessing response to therapy for various reasons:
(a) inability to distinguish between residual fibrosis and residual active tumor;
(b) anatomical regression usually lags behind metabolic cell death.
The advantages of FDG-PET are that metabolic change usually precedes anatomic regression, and residual masses can be characterized as metabolically active tumor or residual fibrosis (Figs 10 and 11 ).
FDG-PET and prognostic implications
Fifteen patients with HD and 17 with aggressive histology NHL with residual masses following therapy underwent [ 18 -F]FDG-PET imaging. Eight of nine patients who were PET positive relapsed. Of 23 patients with PET negative scans only to relapsed (8.7%) ( Table 6 ). Both these patients had aggressive NHL histology and none of the 11 HD patients with PET negative scans relapsed. [ 18 -F]FDG-PET imaging can differentiate between residual masses that are fibrotic and those containing viable tumor (Fig. 11 ) [20] .
Conclusion
As FDG-PET/CT is now being accepted as a valid and useful clinical tool in oncology, major insurance carriers are willing to cover its cost. Its initial use in a limited number of malignancies is now being expanded and it may become the standard and possibly the single imaging modality that will be used to detect, stage cancer and monitor its response to therapy. As FDG has limitations in the diagnosis of some malignancies such as those involving the genitourinary tract, as well as for detecting hypoxia, etc., various new tracers are being developed which will enhance the existing value of PET imaging.
